

11 March 2024

## Botanix to Present at Euroz Hartleys Institutional Conference

### Key highlights

- Botanix Pharmaceuticals will participate in the annual Euroz Hartleys Institutional Conference being held March 12–14 on Rottnest Island
- Botanix CEO Dr Howie McKibbon will be among the featured presenters tomorrow at the renowned “Rotto” Conference
- Botanix Executive Chairman Vince Ippolito will also take part in a panel discussion with Australia-based life science companies
- The Conference brings together institutional and sophisticated investors from around Australia and internationally, to showcase small to mid-cap companies with a Western Australian focus
- Botanix will provide an update on progress towards commercialisation of *Sofdra*<sup>™</sup>, which remains on track for FDA approval in late June 2024, as launch readiness activities accelerate

**Philadelphia and Phoenix US, 11 March 2024:** Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”), is pleased to announce the Company’s participation in the annual Euroz Hartleys Institutional Conference being held March 12–14 on Rottnest Island. Botanix CEO Dr Howie McKibbon is among the featured presenters tomorrow at the Conference and Executive Chairman Vince Ippolito will also take part in a panel discussion with Australia-based life science companies.

The Conference brings together institutional and sophisticated investors around Australia and internationally to showcase small to mid-cap companies with a Western Australian focus. Botanix will provide an update on progress towards commercialisation of *Sofdra*<sup>™</sup>, which remains on track for FDA approval in late June 2024, as launch readiness activities accelerate.

A copy of the presentation being given by the Company is attached to this press release.

This ASX announcement is authorised for release by the Board.

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis through FDA approval. FDA accepted the resubmission of the NDA for *Sofdra* in January 2024 as a complete response and confirmed a target approval timing for late June 2024. *Sofdra* is positioned to be a leading first line and second line therapy and potentially represents a safe and effective new option for patients.

The Company also has a pipeline of other products in late-stage clinical development for range of other dermatology conditions. To learn more please visit: <http://www.botanixpharma.com/>

**For more information, please contact:**

**General enquiries**

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

**Investor enquiries**

Hannah Howlett

WE Communications

P: +61 450 648 064

[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

**Media enquiries**

Haley Chartres

H^CK

P: +61 423 139 163

[haley@hck.digital](mailto:haley@hck.digital)

**Cautionary Note on Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs, the Company's ability to obtain marketing approvals for its product candidates, the expected timing and/or results of regulatory approvals and the outcome and effects of *Sofdra* and the market for *Sofdra*. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. Likewise, comments from the FDA do not reflect a final decision on the information reviewed as part of any NDA submission and should not be construed to do so. These comments are preliminary and may be subject to change as FDA finalizes its review of any NDA and FDA may also identify other information that must be provided before any application can be approved. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

For personal use only

# Euroz Hartleys Rottnest Island Institutional Conference

March 2024

ersonal use only

# Botanix – accelerating towards commercialization of Sofdra™

## DERMATOLOGY FOCUS

New treatments for underserved common skin diseases, with an initial focus on excessive sweating (“primary axillary hyperhidrosis”)

## TOPICALLY DRIVEN

Targeting key indications with topical (gel) treatments that are designed for safety, tolerability, and clinical efficacy

## EXPERIENCED TEAM

US-based team that has been responsible for successful development and commercial launches of more than 30 dermatology drugs

## NEW PRODUCT “SOFDRA”

Sofpironium Bromide (*Sofdra*)<sup>1</sup> is the first and only new chemical entity developed for primary axillary hyperhidrosis (5% strength approved in Japan with solid sales)<sup>2</sup>

## TARGETING MID-24 FDA APPROVAL

Resubmission of NDA for approval was completed in late December 2023; targeting FDA approval in late June 2024

# Corporate Overview



Well-funded to FDA approval, supported by leading life science institutional investors

## ASX: BOT TRADING INFORMATION

Share price	A\$0.185
6-month low / high	A\$0.12/0.20
Shares outstanding	1,563,437,373
<b>Market Capitalization</b>	<b>A\$275m</b>
Cash	A\$ 18.3m
Debt	Nil

## SUBSTANTIAL SHAREHOLDERS


Shareholder	%
Antares Capital	9.0%
Board and Management	7.0%
Top 20	33%



# Hyperhidrosis

A medical condition where excessive sweating occurs beyond what is needed to maintain normal body temperature

- ❖ Hyperhidrosis affects ~16M people in the US<sup>1</sup>
- ❖ Results from overstimulation of the nervous system (a physiological not psychological condition)<sup>1</sup>
- ❖ 90% of axillary (underarm) patients also have it in a second region<sup>1</sup>
- ❖ The most common age of onset for axillary hyperhidrosis patients is 12–17<sup>2</sup>
- ❖ **Market for treatments is ~\$US1.6B per annum—projected to grow to \$US2.8B by 2030<sup>2</sup>**



FREQUENTLY  
CHANGE  
CLOTHES



FRESHEN UP  
BY WIPING OR  
BATHING



PLACE NAPKINS OR  
PADS UNDER THEIR  
ARMS OR THEIR  
POCKETS



HIDE UNDER  
DARK-COLOURED,  
BULKY CLOTHES

# Our lead asset: Sofpironium Bromide (*Sofdra*)<sup>1</sup>

The only new chemical entity developed specifically for the treatment of primary axillary hyperhidrosis

- ❖ Met both co-primary endpoints in two Phase 3 trials<sup>2</sup>
  - 60% of subjects had  $\geq 2$ -point improvement in HDSM-Ax
  - 65% had a significant reduction in GSP sweat production
- ❖ Met all secondary endpoints including clinically meaningful effect on 85% of patients
  - $\geq 1$ -point improvement in HDSM-Ax
  - Statistically significant improvement
- ❖ Favorable tolerability and safety profile<sup>3</sup>
  - Well-tolerated with adverse events that were mostly mild or moderate, and events were transient



Proposed packaging subject to FDA approval

Personal use only

1. Sofdra (sofpironium bromide gel, 15%) is an investigational drug and is not FDA approved. The Sofdra brand name is under review by FDA  
2. Two identical randomized, double-blinded, vehicle-controlled Phase 3 trials for primary axillary hyperhidrosis (pooled; sofpironium bromide gel, 15% n=353; vehicle n=348)  
3. Dry mouth and blurred vision were the predominant treatment-emergent adverse events at 14.4% and 8.5%, respectively, and are common among anticholinergic drugs

# Innovative launch strategy to accelerate adoption following approval

Rapidly establish *Sofdra* as a safe and effective first line treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

- Drive Derm adoption through comprehensive engagement around a compelling clinical story
- Engage and motivate patients to take control of their hyperhidrosis by visiting a telemedicine doctor for a diagnosis and prescription
- Maximize favorable coverage
- Provide patient access and immediate fulfillment through telemedicine and pharmacy network with mail-order fulfillment to drive trial while ensuring compliance
- Hire and train a highly effective Sales Force



# Planned launch activities targeting high prescribers of HH products

In-office rep activities will include video, animation, and printed leave behinds

Digital advertising to drive targeted prescribers to SofdraHCP.com




Images of marketing materials are for representative purposes only

# Patient launch activities to target active HH information seekers

Planned search engine optimization/marketing and all materials will drive patients to Sofdra.com

Planned social media and digital advertising will drive patients to quiz on Sofdra.com

Personal use only



Images of marketing materials are for representative purposes only

# Proactive, pre-approval engagement with Payors with >200K lives

Optimize access ahead of planned launch

Rx Con PBM	Account	Lives	Rnk	Clin Pres
CVS	CVS Caremark - Advanced Control, Performance Standard Control, Value	1,845,000	1	Yes
EXPRESS	Express Scripts - High Performance, Basic	1,718,678	1	Yes
Rx Con PBM	Account	Lives	Rnk	Clin Pres
EMISAR				
ASCENT				
ASCENT	ZINC CVS Caremark - Advanced Control, Performance Standard Control, Value	30,650,000	1	Yes
N/A	ASCENT Express Scripts - National Preferred Formulary	26,709,534	1	Yes
ZINC	EMISAR OptumRX Premium Standard, Value, Select Standard	15,435,000	1	Yes
PROCARE	ZINC Anthem Essential HMO, PPO, National, Traditional	12,833,835	2	Yes
PRIME	EMISAR United Healthcare- Access, Advantage, Choice, Essential, Flex	12,658,000	2	Yes
ASCENT	ASCENT Cigna- Advantage, National Preferred, Performance	8,760,900	2	No
EMISAR	KAISER Kaiser Permanente	8,303,484	1	Yes
EMISAR	TRICARE TriCare	7,214,213	2	Yes
EMISAR	ZINC AETNA- Open, Standard, Fully Insured	5,958,336	2	Yes
DIVIDEND	CVS (FEHBP)- Basic, Focus, Standard	5,330,051	1	Yes
NAVITUS	DoD DEPARTMENT OF VETERANS AFFAIRS	4,701,838	2	Yes
	PRIME BCBS IL/ Tx/NM/MT (HCSC)- HMO or PPO Enhanced, Performance, Multi Tier	4,575,000	2	No
	ASCENT Prime Therapeutics	2,460,000	2	Yes
	PRIME BCBS FL- HMO, PPO Multi Tier	2,125,000	2	No

- ❖ Completed Payor profiles and engagement plan
- ❖ Engaged target Payors around unmet need in primary axillary hyperhidrosis and *Sofdra* value proposition
- ❖ Confirmed hyperhidrosis reimbursement status as medical condition
- ❖ Commenced initial discussions with target Payors responsible for 80% of covered lives

# Docs will e-prescribe directly to our national pharmacy network

- ❖ Instructions are provided to patient in doctor's office when prescription is written
- ❖ Strong value and convenience messaging includes capping patient's out-of-pocket cost
- ❖ QR code to enter instantly into digital space and begin interaction with our pharmacy network
- ❖ Pharmacy mails *Sofdra* the same day that the patient completes their intake form




Images of marketing materials are for representative purposes only


# Territories created based on prescriptions and HH diagnosis data

National programs focused on educating physicians and office staff

Territories aligned with  
prescriber and HH Data



Targeted cities based on  
prescriber and HH data



# Focused pre-launch period ahead

- ❖ FDA approval targeted for late June 2024
- ❖ The issue being considered by the FDA is related to patient Instructions For Use—no efficacy, safety or manufacturing issues remain
- ❖ Commercial preparation is accelerating in anticipation of FDA approval
- ❖ Company is funded through approval and has multiple commercialization options



## Important Notice & Disclaimer

### 1. Summary information

This presentation has been prepared by Botanix Pharmaceuticals Ltd ("Botanix") and contains summary information about Botanix and the business conducted by it which is current as at the date of this presentation ("Presentation") (unless otherwise indicated).

The information in this Presentation is general in nature and does not purport to be accurate nor complete, nor does it contain all of the information that an investor may require in evaluating a possible investment in Botanix, nor does it contain all the information which would be required in a disclosure document or prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). It has been prepared by Botanix with due care but no representation or warranty, express or implied, is provided in relation to the accuracy, reliability, fairness or completeness of the information, opinions or conclusions in this Presentation by Botanix or any other party.

The information in this Presentation remains subject to change without notice. Reliance should not be placed on information or opinions contained in this Presentation, and Botanix does not have any obligation to finalise, correct or update the content of this Presentation. Certain data used in this Presentation has been obtained from research, surveys or studies conducted by third parties, including industry or general publications.

To the maximum extent permitted by law, Botanix is not responsible for updating, nor undertakes to update, this Presentation. It should be read in conjunction with Botanix's other periodic and continuous disclosure announcements lodged with the ASX, which are available at [www2.asx.com.au](http://www2.asx.com.au) or at <https://botanixpharma.com/category/asx-releases/>.

### 2. Not an offer

Neither this Presentation nor any of its contents will form the basis of any understanding, proposal, offer, invitation, contract or commitment.

### 3. Industry data

Certain market and industry data used in connection with or referenced in this Presentation has been obtained from public filings, research, surveys or studies made or conducted by third parties, including as published in industry-specific or general publications. Neither Botanix nor its advisers, or their respective representatives, have independently verified any such market or industry data.

### 4. Financial data

All dollar values are in United States dollars (\$) or US\$) unless otherwise stated. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amounts presented.

### 5. Forward-looking statements and forecasts

This Presentation contains certain "forward-looking statements" and comments about future matters. Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company's strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements. Any such statements, opinions and estimates in this Presentation speak only as of the date hereof, are preliminary views and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct.

Any such forward looking statements are also based on assumptions and contingencies which are subject to change and which may ultimately prove to be materially incorrect, as are statements about market and industry trends, which are based on interpretations of current market conditions. Investors should consider the forward looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements (particularly in light of the current economic climate and significant volatility, uncertainty and disruption caused by the COVID-19 pandemic). The forward looking statements in this Presentation are not guarantees or predictions of future performance and may involve significant elements of subjective judgment, assumptions as to future events that may not be correct, known and unknown risks, uncertainties and other factors, many of which are outside the control of Botanix. Performance of any of the activities mentioned in this Presentation are dependent on funding being available at the relevant time and the activities may therefore change, or not be undertaken at all.

Except as required by law or regulation, Botanix undertakes no obligation to finalise, check, supplement, revise or update forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events or results or other factors affect the information contained in this Presentation. Botanix may also change the order or nature of the activities at its discretion and without notice.

### 6. No liability

The information contained in this document has been prepared in good faith by Botanix. Neither Botanix, nor any of its advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, advisers, employees and agents have authorised, permitted or caused the issue, lodgement, submission, dispatch or provision of this Presentation in a final form and none of them makes or purports to make any binding statement in this Presentation and there is no statement in this Presentation which is based on any statement by them.

To the maximum extent permitted by law, Botanix and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents:

expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any estimates or projections and any other financial information derived therefrom, whether by way of negligence or otherwise; and expressly exclude and disclaim all liabilities in respect of, make no representations regarding, any part of this Presentation and make no representation or warranty as to the currency, accuracy, adequacy, reliability or completeness or fairness of any statements, estimates, options, conclusions or other information contained in this Presentation.

## Operations:

150 N Radnor Chester Road  
Suite A210  
Wayne PA 19087

## Corporate Office:

D2, 661 Newcastle Street  
Leederville W. Australia 6007



Authorised for release by Vince Ippolito, Executive Chairman